Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry

Author:

Daimee Usama A.1ORCID,Wang Yongfei2ORCID,Masoudi Frederick A.3ORCID,Varosy Paul D.3,Friedman Daniel J.24,Du Chengan2,Koutras Cristina5,Reddy Vivek Y.6ORCID,Saw Jacqueline7ORCID,Price Matthew J.8ORCID,Kusumoto Fred M.9ORCID,Curtis Jeptha P.24ORCID,Freeman James V.24ORCID

Affiliation:

1. Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD (U.A.D.).

2. Center for Outcomes Research and Evaluation Yale New Haven Health Services Corporation, New Haven, CT (Y.W., D.J.F., C.D., J.P.C., J.V.F.).

3. Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (F.A.M., P.D.V.).

4. Section of Cardiovascular Medicine (D.J.F., J.P.C., J.V.F.), Yale University School of Medicine, New Haven, CT.

5. American College of Cardiology Foundation, Washington, DC (C.K.).

6. Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY (V.Y.R.).

7. Division of Cardiology, Vancouver General Hospital, The University of British Columbia (J.S.).

8. Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA (M.J.P.).

9. Department of Cardiovascular Disease, Mayo Clinic, Jacksonville, FL (F.M.K.).

Abstract

Background: The Food and Drug Administration approved left atrial appendage occlusion with the Watchman device for patients who are at increased stroke risk and are suitable for oral anticoagulation but who have an appropriate reason to seek a nondrug alternative. These broad criteria raise the question of their interpretation in clinical practice. There is a lack of studies comprehensively evaluating the indications for Watchman implantation among a large series of patients from contemporary, real-world practice in the United States. Methods: We used the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry to identify Watchman procedures performed between 2016 and 2018. We assessed procedural indications for Watchman implantation in the United States and evaluated the association between procedural indications and in-hospital adverse events. Results: A total of 38 314 procedures were included. The mean patient age was 76.1±8.1 years, and 58.9% were men. The mean CHA 2 DS 2 -VASc score was 4.8±1.5, whereas the mean hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol (HAS-BLED) score was 3.0±1.1. Prior stroke or transient ischemic attack was reported in 40.2% and prior bleeding in 70.1%, with gastrointestinal bleeding being most common (41.9%). The most common site-reported procedural indications for Watchman implantation were increased thromboembolic risk (64.8%) and history of major bleed (64.3%), followed by high fall risk (35.5%). Most (71.9%) had ≥2 procedural indications. Patients with high fall risk had increased risk of in-hospital adverse events (adjusted OR, 1.12; P =0.025), but no other differences were found in the risk of in-hospital adverse events by procedural indication. Conclusions: Among patients in the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry, the most common procedural indications for Watchman implantation were increased thromboembolic risk, history of major bleed, and high fall risk. A majority of patients had multiple procedural indications. High fall risk conferred a modestly increased risk of in-hospital adverse events.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3